Mengistu Tadesse
Overview
Explore the profile of Mengistu Tadesse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diriba G, Alemu A, Yenew B, Ayano B, Hailu M, Buta B, et al.
J Glob Antimicrob Resist
. 2025 Feb;
PMID: 39988072
Objectives: To estimate the proportion of second-line anti-tuberculosis drug resistance among multidrug-resistant tuberculosis (MDR-TB) patients in Ethiopia. Methodology: A laboratory-based prospective cross-sectional study was conducted at the National Tuberculosis Reference...
2.
Seid G, Alemu A, Diriba G, Hailu M, Wondimu A, Tadesse M, et al.
PLoS One
. 2025 Feb;
20(2):e0316903.
PMID: 39964990
Background: There was a 'missing millions' gap between the incidence of tuberculosis (TB) cases and the notified cases. In many TB high-burden countries, only about 25% of household contacts (HHCs)...
3.
Yenew B, Ghodousi A, Diriba G, Tesfaye E, Cabibbe A, Amare M, et al.
Nat Commun
. 2023 Nov;
14(1):7519.
PMID: 37980337
The Mycobacterium tuberculosis complex (MTBC) includes several human- and animal-adapted pathogens. It is thought to have originated in East Africa from a recombinogenic Mycobacterium canettii-like ancestral pool. Here, we describe...
4.
Diriba G, Alemu A, Tola H, Eshetu K, Yenew B, Amare M, et al.
IJID Reg
. 2022 Oct;
5:97-103.
PMID: 36247095
Objective: This study aimed to determine the frequencies and trends of and rifampicin resistance among presumptive tuberculosis patients in Ethiopia, who were tested using the Xpert MTB/RIF assay between 2014...
5.
Diriba G, Alemu A, Tola H, Yenew B, Amare M, Eshetu K, et al.
IJID Reg
. 2022 Sep;
5:39-43.
PMID: 36176268
Background: The rise of drug-resistant tuberculosis (DR-TB) has presented a substantial challenge to the national tuberculosis (TB) control program. Understanding the epidemiology of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) could help clinicians...
6.
Sinshaw W, Kebede A, Bitew A, Tadesse M, Mehamed Z, Alemu A, et al.
Afr J Lab Med
. 2022 Sep;
11(1):1671.
PMID: 36091348
Background: There is limited information on the performance of the Xpert MTB/RIF test for diagnosis of smear-negative pulmonary tuberculosis (SNPT) and rifampicin resistance (RR) in the same-day diagnosis approach. The...
7.
Abebaw Y, Kebede A, Eshetu K, Tesfaye E, Tadesse M, Sinshaw W, et al.
PLoS One
. 2022 Jun;
17(6):e0269601.
PMID: 35679308
Introduction: The quality of tuberculosis laboratory services in health facilities is a mandatory component of detecting active pulmonary TB cases and treatment follow-up. However, ensuring the quality of laboratory test...
8.
Diriba G, Kebede A, Tola H, Alemu A, Yenew B, Moga S, et al.
SAGE Open Med
. 2022 Jun;
10:20503121221098241.
PMID: 35646363
Introduction: Molecular tests allow rapid detection of and drug resistance in a few days. Identifying the mutations in genes associated with drug resistance may contribute to the development of appropriate...
9.
Meaza A, Tesfaye E, Mohamed Z, Zerihun B, Seid G, Eshetu K, et al.
PLoS One
. 2021 Dec;
16(12):e0261084.
PMID: 34962949
Background: Rapid and sensitive Tuberculosis (TB) diagnosis closer to patients is a key global TB control priority. Truenat assays (MTB, MTB Plus, and MTB-RIF Dx) are new TB molecular diagnostic...
10.
Diriba G, Kebede A, Tola H, Alemu A, Yenew B, Moga S, et al.
Tuberc Res Treat
. 2021 Sep;
2021:5239529.
PMID: 34589236
Background: In Ethiopia, tuberculosis (TB) is one of the most common causes of illness and death. However, there is limited information available on lineages associated with drug resistance among extrapulmonary...